Anti-Müllerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. En savoir plus sur Anti-Müllerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH.
The Anterolateral Ligament: An Anatomic Study on Sex-Based Differences. En savoir plus sur The Anterolateral Ligament: An Anatomic Study on Sex-Based Differences.
Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiative. En savoir plus sur Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiative.
Does geographical variability influence 5-year MACCE rates in the multicenter SYNTAX revascularization trial? En savoir plus sur Does geographical variability influence 5-year MACCE rates in the multicenter SYNTAX revascularization trial?
Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. En savoir plus sur Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.
Two Paradigms for Endovascular Thrombectomy After Intravenous Thrombolysis for Acute Ischemic Stroke. En savoir plus sur Two Paradigms for Endovascular Thrombectomy After Intravenous Thrombolysis for Acute Ischemic Stroke.
[Comparison of refraction with or without cycloplegia using Retinomax(®) or Plusoptix(®) devices]. En savoir plus sur [Comparison of refraction with or without cycloplegia using Retinomax(®) or Plusoptix(®) devices].
Comparison of the performance and safety of 2 ophthalmic viscosurgical devices in cataract surgery. En savoir plus sur Comparison of the performance and safety of 2 ophthalmic viscosurgical devices in cataract surgery.
Vibrating-mesh nebulizer maintenance by CF patients: Results from a French survey. En savoir plus sur Vibrating-mesh nebulizer maintenance by CF patients: Results from a French survey.
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. En savoir plus sur First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.